Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acting US FDA Chief Sharpless Pledges "Full Speed Ahead" On Agency's Current Agenda

Executive Summary

In his first speech to agency staff, Acting Commissioner Norman Sharpless says FDA will continue working on issues including drug pricing and opioids – and he is not approaching the post like a temporary caretaker. 

You may also be interested in...



Hahn Confirmation Hearing: Pharma May Be Left Parsing Non-Rx Questions For Policy Clues

US FDA commissioner nominee could face a slew of questions about non-drug issues such as e-cigarette regulation, which may mean pharma must read between the lines for insight into his drug-related policy stances.

Acting Commissioner Giroir Emphasizes 'Transitional' Period, Suggesting Time At US FDA Will Be Short

Giroir's memo to FDA staff also says intends to coordinate with prior acting commissioner Norman Sharpless to ensure current activities continue.

Former FDA Commissioners Push For Sharpless Nomination, Confirmation

Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.

Related Content

Topics

UsernamePublicRestriction

Register

PS125130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel